CA Patent

CA2822701A1 — Novel pharmaceutical composition

Assigned to Novartis AG · Expires 2012-06-28 · 14y expired

What this patent protects

Disclosed are novel pharmaceutical compositions containing N-{3-[3- cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy a…

USPTO Abstract

Disclosed are novel pharmaceutical compositions containing N-{3-[3- cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same.

Drugs covered by this patent

trametinib-dimethyl-sulfoxide (TRAMETINIB DIMETHYL SULFOXIDE)

Patent Metadata

Patent number: CA2822701A1
Jurisdiction: CA
Classification: —
Expires: 2012-06-28
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.